Omeros (OMER) Stock Forecast & Price Target

Omeros is viewed favorably because Yartemlea’s U.S. launch is already showing strong traction, with 2Q sales of $28.5M, 74 unique ordering accounts, and about 75% of orders from adults, suggesting broadening adoption in a large transplant population. The analyst’s work implies the drug could reach roughly 35%-40% U.S. market share and about $400M in peak sales even with almost no Europe contribution, while reimbursement tailwinds from the permanent J-code and NTAP should further reduce friction starting in 3Q26 and 4Q26. Although the negative CHMP opinion in June remains an overhang, it is not thesis-breaking because the U.S. launch is already the primary value driver and Europe would be incremental upside rather than required to support the outlook.

Omeros is facing a materially negative fundamental backdrop because the June CHMP rejection highlighted a pivotal-study flaw: the lack of a comparator arm, which made it difficult to isolate Yartemlea’s effect, while the pediatric dataset was also judged insufficient to support the proposed dose and establish efficacy and safety in children. The company is heavily dependent in the near term on narsoplimab (OMS721), so any approval failure or weaker-than-forecast commercial sales could directly pressure valuation and delay profitability. Although the U.S. YARTEMLEA launch and NVO partnership are supportive, the EU setback reduces the opportunity set and underscores pipeline and regulatory execution risk.